首页> 外文期刊>Acta Crystallographica, Section B. Structural Science >Cocrystals of 5-fluorocytosine. I. Coformers with fixed hydrogen-bonding sites
【24h】

Cocrystals of 5-fluorocytosine. I. Coformers with fixed hydrogen-bonding sites

机译:5-氟胞嘧啶的共晶体。 I.具有固定氢键位的共聚体

获取原文
获取原文并翻译 | 示例
       

摘要

The antifungal drug 5-fluorocytosine (4-amino-5-fluoro-1,2- dihydropyrimidin-2-one) was cocrystallized with five complementary compounds in order to better understand its drug-receptor interaction. The first two compounds, 2-aminopyrimidine (2-amino-1,3-diazine) and N-acetylcreatinine (N-acetyl-2-amino-1-methyl-5H-imidazol-4-one), exhibit donor-acceptor sites for R 2 ~2(8) heterodimer formation with 5-fluorocytosine. Such a heterodimer is observed in the cocrystal with 2-aminopyrimidine (I); in contrast, 5-fluorocytosine and N-acetylcreatinine [which forms homodimers in its crystal structure (II)] are connected only by a single hydrogen bond in (III). The other three compounds 6-aminouracil (6-amino-2,4-pyrimidinediol), 6-aminoisocytosine (2,6-diamino-3H-pyrimidin-4-one) and acyclovir [acycloguanosine or 2-amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6- one] possess donor-donor-acceptor sites; therefore, they can interact with 5-fluorocytosine to form a heterodimer linked by three hydrogen bonds. In the cocrystals with 6-aminoisocytosine (Va)-(Vd), as well as in the cocrystal with the antiviral drug acyclovir (VII), the desired heterodimers are observed. However, they are not formed in the cocrystal with 6-aminouracil (IV), where the components are connected by two hydrogen bonds. In addition, a solvent-free structure of acyclovir (VI) was obtained. A comparison of the calculated energies released during dimer formation helped to rationalize the preference for hydrogen-bonding interactions in the various cocrystal structures.
机译:为了更好地了解其药物-受体相互作用,将抗真菌药物5-氟胞嘧啶(4-氨基-5-氟-1,2-二氢嘧啶-2-一)与五个互补化合物共结晶。前两个化合物2-氨基嘧啶(2-氨基-1,3-二嗪)和N-乙酰肌酐(N-乙酰基-2-氨基-1-甲基-5H-咪唑-4-酮)表现出供体-受体位点与5-氟胞嘧啶形成R 2〜2(8)异二聚体。在与2-氨基嘧啶(I)的共晶体中观察到了这种异二聚体。相反,5-氟胞嘧啶和N-乙酰肌酐[在其晶体结构(II)中形成同型二聚体]仅通过(III)中的单个氢键连接。其他三种化合物6-氨基尿嘧啶(6-氨基-2,4-嘧啶二醇),6-氨基异胞嘧啶(2,6-二氨基-3H-嘧啶-4-酮)和阿昔洛韦[无环鸟苷或2-氨基-9-[( [2-羟基乙氧基)甲基] -1,9-二氢-6H-嘌呤-6-一个]具有供体-供体-受体位点;因此,它们可以与5-氟胞嘧啶相互作用形成通过三个氢键连接的异二聚体。在具有6-氨基异胞嘧啶(Va)-(Vd)的共晶体中,以及在与抗病毒药物阿昔洛韦(VII)的共晶体中,观察到所需的异二聚体。但是,它们在与6-氨基尿嘧啶(IV)的共结晶中并未形成,后者的成分通过两个氢键连接。另外,获得了无溶剂的阿昔洛韦(VI)结构。比较二聚体形成期间释放的计算出的能量有助于合理化各种共晶体结构中氢键相互作用的偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号